CymaBay Therapeutics Inc. is scrapping two mid-stage trials of the liver disease drug seladelpar after biopsies found a type of liver damage in some patients, sending the company’s shares down more than 75 percent.
2016 Annual Report: State Of The Bio Industry
Acute Myeloid Leukemia (AML), Analysts, Approvals, Biliary Atresia, Biopharma, Biotech, Biotech/Biopharma, Biotechnology, Checkpoint Inhibitors, Farnesoid X Receptor (FXR) Agonists, Forecasts, Immune System, Immune Systems, Immuno-oncology, Issue Archives, June 2016, Liver Disease, M&A, M&A, Nonalcoholic Steatohepatitis (NASH), PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Pricing, Primary Sclerosing Cholangitis (PSC), Special Reports, T-CellsThe outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
